Julia K. Rotow, MD, provided potentially practice-changing updates from ESMO 2023, particularly in advanced non–small cell lung cancer (NSCLC).
Beginning with a study of adjuvant alectinib for ALK-positive NSCLC in the ALINA trial, Dr Rotow proceeded to discuss results in the ADAURA and KEYNOTE-671 trials in early-stage lung cancer. In advanced NSCLC, Dr Rotow highlighted the much-anticipated results in the setting of EGFR-mutant lung cancer. For patients with EGFR exon 20 insertion-mutated advanced NSCLC, Dr Rotow noted a likely new standard of care in the results from the PAPILLON trial which studied combining the EGFR-MET bispecific antibody with chemotherapy in the first-line setting for this patient population. The overview concluded in summarizing the results from the MARIPOSA and MARIPOSA-2 trials, the latter examining the combination of amivantamab and chemotherapy with or without lazertinib compared with chemotherapy alone in the acquired-resistance setting.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ESMO 2023: Key Highlights in Advanced NSCLC - Medscape - Oct 27, 2023.
Comments